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Introduction
Type I interferons (IFN-Is) are critical for controlling various viral infections (1, 2), but the precise role of  
IFN-Is during chronic HIV-1 infection is still not clearly defined (3, 4). HIV-1 infection induces sustained 
expression of  IFN-Is (5, 6). It has been shown that IFN-Is can suppress HIV-1 replication in vitro (3). 
IFN-Is have also been shown to inhibit initial simian immunodeficiency virus (SIV) infection in rhesus 
macaques (7) and HIV-1 infection in humanized mice (8, 9) in vivo. Furthermore, reports also indicated 
that transmitted/founder viruses isolated from patients are less sensitive to suppression by IFN-α in cultured 
cells than their corresponding viruses present during chronic infection, suggesting that resistance to IFN-I–
mediated inhibition may provide a selective advantage during transmission and initial infection (10, 11). 
These observations suggest that a robust IFN-I response helps to control early HIV-1 and SIV infection.
The contribution of  IFN-Is to the control of  HIV-1 replication and to the immunopathogenesis of  
AIDS during chronic infection is under debate (3, 4). Recently, studies using nonhuman primate models 
show that sustained IFN-I signaling is associated with pathogenic SIV infection. IFN-Is are equally 
induced during acute SIV infection in both nonpathogenic (African green monkeys or sooty mangabeys) 
and pathogenic (rhesus macaques or pigtail macaques) hosts. However, compared with the nonpathogenic 
infection, pathogenic SIV infection of  rhesus macaques leads to AIDS correlating with persistent IFN-I 
signaling (12–15). These studies imply that there is a correlation between IFN-I signaling and SIV-induced 
pathogenesis, although it is unclear whether the ability of  the natural hosts to shut off  the IFN-I response 
directly contributes to the outcomes or is a secondary effect. Supportively, in persistent lymphocytic 
choriomeningitis virus (LCMV) infection in mice, blocking IFN-I signaling can reduce immune activation, 
diminish immune suppression, restore lymphoid architecture, and accelerate clearance of  the virus (16–18).
The direct link between sustained type I interferon (IFN-I) signaling and HIV-1–induced 
immunopathogenesis during chronic infection remains unclear. Here we report studies using 
a monoclonal antibody to block IFN-α/β receptor 1 (IFNAR1) signaling during persistent HIV-1 
infection in humanized mice (hu-mice). We discovered that, during chronic HIV-1 infection, IFNAR 
blockade increased viral replication, which was correlated with elevated T cell activation. Thus, 
IFN-Is suppress HIV-1 replication during the chronic phase but are not essential for HIV-1–induced 
aberrant immune activation. Surprisingly, IFNAR blockade rescued both total human T cell and HIV-
specific T cell numbers despite elevated HIV-1 replication and immune activation. We showed that 
IFNAR blockade reduced HIV-1–induced apoptosis of CD4+ T cells. Importantly, IFNAR blockade also 
rescued the function of human T cells, including HIV-1–specific CD8+ and CD4+ T cells. We conclude 
that during persistent HIV-1 infection, IFN-Is suppress HIV-1 replication, but contribute to depletion 
and dysfunction of T cells.
2Administration of  exogenous IFN-α was reported to lower HIV-1 burden but failed to show a 
significant benefit in HIV-1 disease progression in HIV-1–infected patients (4). Association studies in 
HIV-1–infected patients indicated that overexpression of  IFN-Is and interferon-stimulated genes (ISGs) 
is correlated with higher levels of  viral load, enhanced hyper-immune activation, and faster rates of  
disease progression (6, 19–21). These reports highlight that IFN-Is may play important but complex 
roles in HIV-1 infection and pathogenesis.
A study by Sandler et al. reported that during the acute phase (0–4 weeks after infection) of  SIV infection, 
blocking IFN-I signaling with an antagonistic mutant recombinant IFN-α2 (IFN-ant), with increased IFN-
α/β receptor 2 (IFNAR2) binding but diminished IFNAR1 binding activity (22), leads to elevated SIV 
replication and accelerated disease progression in rhesus monkeys (7). However, this report only defined the 
role of  IFN-Is during acute SIV infection. The role of  IFN-Is during chronic SIV infection is still unclear.
To clarify the causal link between sustained IFN-I signaling and HIV-1–induced immunopathogenesis, 
we developed a mAb against IFNAR1 to block IFN-I signaling during persistent HIV-1 infection in 
Figure 1. Persistent HIV-1 infection in humanized mice leads to sustained and systemic type I IFN expression and IFN-stimulated gene induction. 
Humanized mice were infected with HIV-1. (A) Plasma HIV-1 genomic RNA levels at indicated time points. (B) Human IFN-α (pan IFN-α) levels in plasma at 
indicated time points and IFN-β levels in plasma at 10.5 weeks post infection (wpi). (C) Relative mRNA levels of Mx2, IFITM3, Trim22, ISG15, OAS1, MxA, 
and IRF7 in peripheral blood mononuclear cells at indicated time points. (D) The relative mRNA levels of Mx2, IFITM3, Trim22, ISG15, OAS1, MxA, and IRF7 
in spleens at termination (10.5 wpi). Shown are representative data (mock, n = 4; HIV-1, n = 5) of 4 independent experiments (mock, n = 12; HIV-1, n = 18 
in total) with mean values ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. Unpaired, 2-tailed Student’s t test was performed to compare between groups at 
singular time points (B and C) or between 2 groups (D).
humanized mice with a functional human immune system (hu-mice). We have 
reported that the anti-IFNAR1 mAb specifically binds human IFNAR1 and 
inhibits human IFN-I activity both in vitro and in vivo (23). We found that 
IFNAR blockade during persistent HIV-1 infection rescued human T cells 
both numerically and functionally, despite elevated HIV-1 replication and T 
cell activation. Thus, IFN-Is contribute to T cell depletion and dysfunction, as 
well as to innate virus control, during persistent HIV-1 infection.
Results
Persistent HIV-1 infection leads to sustained and systemic IFN-I induction. To 
functionally define the role of  IFN-Is in persistent HIV-1 infection and 
pathogenesis, we employed hu-mice for modeling HIV-1 infection and 
immunopathogenesis (24–26). HIV-1 infection in hu-mice resulted in sustained 
plasma viremia (Figure 1A). Similar to clinical observations (4, 27), HIV-1 
infection in hu-mice also led to induction of  IFN-Is including IFN-α and IFN-β 
(Figure 1B) and the induction of  ISGs, including Mx2, IFITM3, Trim22, 
ISG15, OAS1, MxA, and IFN regulatory factor 7 (IRF7) both in peripheral 
blood mononuclear cells (PBMCs) (Figure 1C) and in the spleen (Figure 1D).
As observed in HIV-1–infected patients, HIV-1 infection in hu-mice 
induced severe depletion of  human leukocytes including CD4+ T cells 
in both peripheral blood and lymphoid organs (Supplemental Figure 1, 
A–E; supplemental material available online with this article; https://doi.
org/10.1172/jci.insight.94366DS1). Persistent HIV-1 infection also led to aberrant T cell activation, 
as indicated by enhanced expression of  HLA-DR, CD38, and Ki-67 (Supplemental Figure 1, F–I). 
Additionally, human T cells in HIV-1–infected mice showed increased expression of  exhaustion markers 
PD-1 and TIM-3 (Figure 2A), which was associated with impaired T cell functions as indicated by decreased 
capacity to produce IFN-γ and IL-2 by both CD8+ and CD4+ T cells upon PMA/ionomycin stimulation 
(Figure 2, B and C). Therefore, persistent HIV-1 infection in hu-mice led to systemic and sustained IFN-I 
signaling associated with CD4+ T cell depletion, aberrant immune activation, and T cell exhaustion.
IFNAR1 blockade during persistent HIV-1 infection elevates HIV-1 replication. To define the role of  IFN-Is 
during persistent HIV-1 infection in vivo, we infected hu-mice and treated them with IFNAR1-blocking 
mAb from 6 to 10 weeks postinfection (wpi). As expected, IFNAR1 mAb treatment blocked the expression 
of  ISGs, including those with anti–HIV-1 function such as Mx2 (28, 29) and IFITM3 (30, 31), in PBMCs 
of  infected hu-mice (Figure 3A and Supplemental Figure 2, A and B). We found that HIV-1 replication 
increased 8-fold within 1 week after IFNAR1 blockade and was sustained at higher levels than in control 
mice from 7 to 10 wpi (Figure 3B). IFNAR1 blocking resulted in higher IFN-α levels in peripheral blood 
(Figure 3C), which correlated with higher HIV-1 viremia in anti-IFNAR1–treated mice. At termination 
(10 wpi), IFNAR1 blockade also blocked ISG expression (Figure 3D and Supplemental Figure 2C) and 
increased HIV-1 replication in the spleen (Figure 3E). These results indicate that, during persistent HIV-1 
infection, IFN-Is still contribute to the suppression of  HIV-1 replication.
Elevated HIV-1 replication correlates with higher levels of  T cell activation and proinflammatory cytokine 
production after IFNAR1 blockade. We found that the frequencies of  CD38/DR–positive and Ki-67–positive 
Figure 2. Persistent HIV-1 infection in humanized mice leads to impaired T cell 
function. Humanized mice were infected with HIV-1 and terminated at 10.5 weeks 
postinfection (wpi). (A) Representative dot plots and summarized data show 
the percentage PD-1+ and TIM-3+ of CD8+ T cells in spleens. (B and C) At 10.5 wpi, 
splenocytes were stimulated ex vivo with PMA/ionomycin for 4 hours followed by 
intracellular cytokine staining. (B) Representative dot plots (of cells gated on human 
CD45+CD3+CD8+) and summarized data show the percentages of IFN-γ–producing and 
IL-2–producing CD8+ T cells. (C) Representative dot plots (of cells gated on human 
CD45+CD3+CD4+) and summarized data show the percentages of IFN-γ–producing and 
IL-2–producing CD4+ T cells. Shown are representative data (mock, n = 4; HIV-1, n = 5) 
of 4 independent experiments (mock, n = 12; HIV-1, n = 18 in total) with mean values ± 
SEM. *P < 0.05, **P < 0.01, ***P < 0.001 by unpaired, 2-tailed Student’s t test.
CD8+ and CD4+ T cells were increased by blocking IFNAR1 (Figure 4, A and B). The expression level of  
CD38/DR and Ki-67 on T cells was positively correlated with HIV-1 viremia in plasma (Figure 4, C and 
D). IFNAR1 blockade also led to increased expression of  TNF-α, MCP-1, IP-10, and IFN-γ in plasma of  
HIV-1–infected hu-mice (Figure 4E). These results indicate that, in the absence of  IFN-I signaling, elevated 
HIV-1 replication was correlated with higher immune activation. Thus, IFN-I signaling is not essential for 
the aberrant T cell immune activation during the chronic phase of  HIV-1 infection.
IFNAR1 blockade during persistent HIV-1 infection rescues human T cells, including HIV-1–specific T cells. 
Systemic chronic immune activation is associated with CD4+ T cell depletion (32, 33). However, the causal 
link between immune activation and CD4+ T cell loss is unclear (32). We therefore analyzed the effect of  
IFNAR1 blockade on HIV-1–induced pathogenesis, including CD4+ T cell depletion. Surprisingly, despite 
increased HIV-1 replication and T cell activation, the number of  human CD4+ T cells in the spleen and 
mesenteric lymph nodes (mLNs) was significantly increased in hu-mice with IFNAR1 blockade (Figure 5, A 
and B). IFNAR1 blockade also rescued human CD8+ T cells and total human leukocytes in lymphoid organs 
(Figure 5, A and B). Furthermore, we found that IFNAR1 blockade significantly increased the percentage 
and number of  HLA-A2/SL-9 (an epitope consisting of  amino acids 77–85 of  HIV-1 p17 protein) pentamer–
specific CD8+ T cells in lymphoid organs (Figure 5, C and D, and Supplemental Figure 3). These results 
suggest that, in the absence of  IFN-I signaling, elevated immune activation does not lead to T cell depletion. 
IFN-I signaling thus contributes to the depletion of  T cells during persistent HIV-1 infection.
IFNAR1 blockade protects HIV-1–induced apoptosis of  CD4+ T cells. Elevated apoptosis is correlated with 
CD4+ T cell depletion during HIV-1 infection (34–36). We detected higher levels of  active caspase-3 in 
CD4+ T cells after persistent HIV-1 infection in hu-mice (Figure 6A). IFNAR1 blockade reduced the level 
of  active caspase-3 in CD4+ T cells (Figure 6A). These results suggest that blockade of  IFN-I signaling 
prevents HIV-1–induced CD4+ T cell apoptosis.
Figure 3. IFNAR1 blockade during persistent HIV-1 infection enhances viral replication in humanized mice. Humanized mice infected with HIV-1 were treated 
from 6 to 10 weeks postinfection (wpi) with a mAb against IFN-α/β receptor 1 (IFNAR1) or isotype control (mouse IgG2a) twice per week. (A) Relative mRNA 
levels of human interferon-stimulated genes including Mx2, IFITM3, TRIM22, and IRF7 in peripheral blood mononuclear cells at 9 wpi. (B) Plasma HIV-1 RNA 
levels at indicated time points after HIV-1 infection. (C) Human IFN-α levels in the plasma after HIV-1 infection. Shown (A–C) are representative data (mock, 
n = 3; HIV-1 + mIgG2a, n = 5; HIV-1 + anti-IFNAR1, n = 5 ) of 3 independent experiments (mock, n = 7; HIV-1 + mIgG2a, n = 11; HIV-1 + anti-IFNAR1, n = 12 in 
total) with mean values ± SEM. (D) Relative mRNA levels of human Mx2, IFITM3, TRIM22, and IRF7 in splenocytes at 10 wpi. (E) Representative FACS plots 
and summarized data show the percentages of HIV-1 p24–positive CD4+ T cells (CD3+CD8–) in the spleen at 10 wpi. Shown (D and E) are combined data of 2 
independent experiments (mock, n = 6; HIV-1 + mIgG2a, n = 9; HIV-1 + anti-IFNAR1, n = 9) with mean values ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. One-
way ANOVA and Bonferroni’s post hoc test were performed to compare between groups at singular time points (B and C) or between groups (A, D, and E).
We then used an ex vivo culture system to further investigate how IFN-I signaling leads to CD4+ T cell 
depletion (37). We isolated splenocytes from hu-mice persistently infected with HIV-1 and cultured them 
ex vivo in the presence of  isotype control Ab, anti-IFNAR1 mAb, or IFN-α. IFNAR1 blockade increased 
HIV-1 replication and exogenous IFN-α inhibited HIV-1 replication (Figure 6B). We found that, as in 
lymphoid organs in vivo, CD4+ T cells from HIV-infected mice showed higher levels of  active caspase-3 
(Figure 6, C and D). IFNAR1 blockade reduced the level of  active caspase-3 in CD4+ T cells (Figure 6, 
C and D). Accordingly, exogenous IFN-α added to the culture system further increased the level of  active 
caspase-3 (Figure 6, C and D). Thus, IFNAR1 blockade rescued HIV-1–induced CD4+ T cell depletion 
despite elevated HIV-1 replication, and exogenous IFN-α accelerated CD4+ T cell depletion (Figure 6E), 
although it inhibited HIV-1 replication. In addition, inhibition of  the activity of  caspase-3 by the specific 
inhibitor Z-DEVD-FMK also reduced HIV-1–induced CD4+ T cell apoptosis and rescued CD4+ T cell 
number (Figure 6, F–H). In contrast, caspase-1 expression in CD4+ T cells did not increase in HIV-1–
infected samples (Supplemental Figure 4) and inhibition of  caspase-1 activity did not prevent CD4+ T cell 
Figure 4. IFNAR1 blockade during persistent HIV-1 infection increases expression of HLA-DR/CD38 and Ki-67 on T cells. Humanized mice infected with 
HIV-1 were treated from 6 to 10 weeks postinfection (wpi) with a mAb against IFN-α/β receptor 1 (IFNAR1) or isotype control (mouse IgG2a) twice per 
week. Mice were sacrificed at 10 wpi. (A) Summarized data show CD8+ and CD4+ T cells expressing HLA-DR/CD38 (mock, n = 9; HIV-1 + mIgG2a, n = 12; 
HIV-1 + anti-IFNAR1, n = 12, combined data from 3 independent experiment with mean values ± SEM). (B) Summarized data show CD8+ and CD4+ T cells 
expressing Ki-67 (mock, n = 6; HIV-1 + mIgG2a, n = 8; HIV-1 + anti-IFNAR1, n = 8, combined data from 2 independent experiments with mean values ± SEM). 
(C) Correlation analysis between HLA-DR/CD38 expression on T cells and plasma HIV-1 RNA levels. (D) Correlation analysis between Ki-67 expression on 
T cells and plasma HIV-1 RNA levels. (E) The levels of indicated cytokines in the plasma of humanized mice at 10 wpi. Shown (E) are combined data of 3 
independent experiments (mock, n = 6; HIV-1 + mIgG2a, n = 9; HIV-1 + anti-IFNAR1, n = 11) with mean values ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 by 
1-way ANOVA and Bonferroni’s post hoc test (A, B, and E) and Spearman rank correlation test (C and D).
depletion (Figure 6I). Taken together, these results indicate that sustained IFN-I signaling contributes to 
apoptosis of  CD4+ T cells during persistent HIV-1 infection.
IFNAR1 blockade rescues function of  human T cells during persistent HIV-1 infection. We next analyzed 
the contribution of  IFN-I signaling to HIV-1–induced functional impairment of  T cells. We found that 
IFNAR1 blockade restored the ability of  both CD8+ and CD4+ T cells to produce IFN-γ and IL-2 upon 
PMA/ionomycin stimulation (Figure 7, A–C and Supplemental Figure 5A). IFNAR1 blockade did not 
reduce the expression level of  PD-1 on T cells (Supplemental Figure 6A), which was correlated with 
more viral replication (Supplemental Figure 6B). We further analyzed the function of  HIV-1–specific 
T cells after IFNAR1 blockade. When stimulated with an HIV-1 Gag peptide pool ex vivo, both CD8+ 
and CD4+ T cells from hu-mice with IFNAR1 blockade produced significantly higher levels of  IFN-γ 
and IL-2 (Figure 7, D–F and Supplemental Figure 5B), indicating that IFNAR1 blockade also rescued 
functional responses of  HIV-1–specific T cells in persistently infected hosts. Taken together, these results 
show that IFNAR1 blockade during persistent HIV-1 infection rescues both the number and function of  
human T cells, including HIV-1–specific T cells.
Discussion
The contribution of  IFN-I signaling to HIV-1 replication and immunopathogenesis during chronic infection 
is not clearly defined (3, 4), although persistent activation of  plasmacytoid dendritic cells (pDCs) has been 
Figure 5. IFNAR1 blockade during persistent HIV-1 infection rescues human T cells and total human leukocytes in humanized mice. Humanized mice 
infected with HIV-1 were treated with a mAb against IFN-α/β receptor 1 (IFNAR1) or isotype control (mouse IgG2a) twice per week from 6 to 10 weeks 
postinjection (wpi). Mice were sacrificed at 10 wpi. (A and B) Numbers of CD4+ T cells (CD3+CD8–), CD8+ T cells (CD3+CD8+) and total human leukocytes in 
spleens (A) (mock, n = 13; HIV-1 + mIgG2a, n = 18; HIV-1 + anti-IFNAR1, n = 17, combined data from 5 independent experiments) and mesenteric lymph 
nodes (mLNs) (B) (mock, n = 8; HIV-1 + mIgG2a, n = 12; HIV-1 + anti-IFNAR1, n = 11, combined data from 3 independent experiments with mean values ± 
SEM). (C and D) Humanized NSG-A2 mice transplanted with hematopoietic stem cells from HLA-A2–matched donor were infected with HIV-1 and treated 
with anti-IFNAR1 mAb or isotype control (mouse IgG2a) twice per week from 6 to 10 wpi. Mice were sacrificed at 10 wpi. Representative dot plots (C) and 
summarized data (D) show the percentages of CD8+ T cells specific for the HLA-A2/SL-9 pentamer (an HLA-A2–restricted epitope consisting of amino acids 
77–85 of HIV-1 p17 protein) among CD8+ T cells from lymph nodes (mock, n = 3; HIV-1 + mIgG2a, n = 3; HIV-1 + anti-IFNAR1, n = 3) and spleens (mock, n = 3; 
HIV-1 + mIgG2a, n = 4; HIV-1 + anti-IFNAR1, n = 4). *P < 0.05, **P < 0.01, ***P < 0.001 by 1-way ANOVA with Bonferroni’s post hoc test.
reported to contribute to HIV-induced immunopathogenesis (37, 38). Using an anti-IFNAR1 mAb to block 
IFN-I signaling in vivo, we showed here that IFNAR1 blockade during persistent HIV-1 infection increased 
HIV-1 replication in hu-mice. We discovered that IFNAR1 blockade rescued human T cells numerically 
and functionally despite elevated HIV-1 replication and T cell activation. Our results agree with recent 
findings showing that persistent IFN-I signaling plays a detrimental role during chronic LCMV infection 
and blocking IFN-I signaling with an anti-IFNAR mAb could reverse T cell exhaustion and enhance 
antiviral immune responses (16, 17).
During the chronic phase of  HIV-1 infection, a positive correlation between the expression of  
ISGs and HIV-1 viremia has been reported (6, 19). Persistent ISG expression is also associated with 
pathogenic SIV infection (12, 13, 15, 39). However, the role of  IFN-I signaling in HIV-1 infection and 
Figure 6. IFNAR1 blockade or inhibition of caspase-3 activity rescues CD4+ T cells from HIV-1–induced depletion. (A) Humanized mice infected with HIV-1 
were treated with a mAb against IFN-α/β receptor 1 (IFNAR1) or isotype control (mouse IgG2a) twice per week from 6 to 10 weeks postinfection (wpi). Mice 
were sacrificed at 10 wpi. Representative dot plots and summarized data (mock, n = 6; HIV-1 + mIgG2a, n = 9; HIV-1 + anti-IFNAR1, n = 9, combined data from 
2 independent experiments with mean values ± SEM) show the percentage splenic CD4+ T cells expressing active caspase-3. (B–E) Splenocytes from mock (n = 
2) or HIV-1–infected (n = 4) humanized mice were cultured with IL-2 (20 U/ml) in vitro in the presence of control mIgG2a (10 μg/ml), anti-IFNAR1 (10 μg/ml) or
IFN-α (200 U/ml) for 10 days. At day 10, the cells were counted and used for analysis. (B) HIV-1 RNA levels in culture supernatant. (C and D) Representative dot
plots (C) and summarized data (D) show the percentages of CD4+ T cells with active caspase-3. (E) Number of live CD4+ T cells in each group. (F–I) Splenocytes
from mock (n = 2) or HIV-1–infected (n = 4) humanized mice were cultured with IL-2 in vitro in the presence of DMSO or caspase-3 inhibitor Z-DEVD-FMK or 
caspase-1 inhibitor Ac-YVAD-CMK for 10 days. At day 10, the cells were counted and used for staining. (F and G) Representative dot plots (F) and summarized
data (G) show the percentages of active-caspase-3+ CD4+ T cells. (H and I) Number of live CD4+ T cells in each group. Data are representative of 2 independent
experiments with mean values ± SEM). *P < 0.05, **P < 0.01 by unpaired, 2-tailed Student’s t test to compare differences between 2 groups. ns, not significant.
disease progression is not clearly defined. We found that blocking endogenous IFN-I signaling during 
persistent HIV-1 infection by anti-IFNAR1 mAb increased viral replication. This result is consistent 
with our previous finding that depletion of  pDCs, the major IFN-I–producing cells during HIV-1 
infection, increased HIV-1 replication (38). Thus, we demonstrate that HIV-1 is still sensitive to IFN-I 
during persistent HIV-1 infection.
HIV-1 disease progression is associated with depletion of  human leukocytes including human CD4+ T 
cells. Although several reports show that persistent ISG induction is correlated with disease progression in 
HIV-1–infected patients (19–21), the direct causal link between IFN-I signaling and CD4+ T cell depletion 
is not clearly established. In the present study, we found that IFNAR1 blockade rescued both the number 
and function of  human T cells, and prevented HIV-1–induced CD4+ T cell apoptosis, in spite of  higher 
levels of  virus replication. Thus, sustained IFN-I signaling plays a major role in CD4+ T cell depletion 
during persistent HIV-1 infection. Interestingly, we found that IFNAR1 blockade increased the expression 
of  activation markers CD38/HLA-DR and Ki-67 on both CD4+ and CD8+ T cells and was positively 
correlated with HIV-1 viremia. These data also indicate that IFN-Is are not essential for HIV-induced 
aberrant immune activation. In the absence of  IFN-I signaling, higher levels of  HIV-1 viremia or aberrant 
immune activation failed to lead to CD4+ T cell depletion. We thus conclude that IFN-Is are critical to the 
death of  human T cells during chronic HIV-1 infection.
Figure 7. IFNAR1 blockade during persistent HIV-1 infection rescues the function of human T cells, including HIV-1–specific T cells. Humanized 
mice infected with HIV-1 were treated with a mAb against IFN-α/β receptor 1 (IFNAR1) or isotype control (mouse IgG2a) twice per week from 6 to 10 
weeks postinfection (wpi). Mice were sacrificed at 10 wpi. (A–C) Splenocytes were stimulated ex vivo with PMA plus ionomycin for 4 hours followed by 
intracellular cytokine staining. Representative dot plots (A) and summarized data show the percentages of CD8+ T cells (B) and CD4+ T cells (C) producing 
IFN-γ (mock, n = 11; HIV-1 + mIgG2a, n = 15; HIV-1 + anti-IFNAR1, n = 13, combined data from 4 independent experiments with mean values ± SEM) or 
IL-2 (mock, n = 8; HIV-1 + mIgG2a, n = 10; HIV-1 + anti-IFNAR1, n = 10, combined data from 3 independent experiments with mean values ± SEM). (D–F) 
Splenocytes were stimulated ex vivo with peptide pools of HIV-1 Gag protein for 8 hours (brefeldin A was added at 3 hours) followed by intracellular 
cytokine staining. Representative dot plots (D) and summarized data show the percentages of CD8+ T cells (E) and CD4+ T cells (F) producing IFN-γ and IL-2 
(mock, n = 4; HIV-1 + mIgG2a, n = 6; HIV-1 + anti-IFNAR1, n = 6, combined data from 2 independent experiment with mean values ± SEM). *P < 0.05, **P < 
0.01, ***P < 0.001 by 1-way ANOVA and Bonferroni’s post hoc test.
IFN-Is also play an important role in modulating T cell function (40). During chronic LCMV infection 
in mice, blocking IFN-I signaling with an anti-IFNAR1 mAb can enhance antiviral immune responses 
and prevent or accelerate clearance of  persistent LCMV infection in mice (16, 17). We demonstrate here 
that during chronic HIV-1 infection in hu-mice, blocking IFN-I signaling rescued the HIV-1–specific T 
cell function. IFNAR blockade may lead to the improvement in anti-HIV-1 T cell responses by several 
mechanisms. First, it has been reported that sustained IFN-I signaling leads to the expression of  the 
negative immune regulators IL-10 and PD-L1 on antigen-presenting cells during LCMV infection in mice. 
Blockade of  IFN-I signaling improves DC functions and may contribute to the restoration of  anti-LCMV 
T cell responses (16, 17, 40). Second, IFNAR signaling in T cells may have direct antiproliferative and 
proapoptotic effects (36, 40–42). In addition, the preservation of  helper CD4+ T cells by blocking IFNAR 
may also help to enhance anti–HIV-1 CD8+ T cell activity. However, blockade of  IFNAR in hu-mice also 
led to elevated HIV-1 replication. This may be due to the loss of  an innate anti–HIV-1 effect of  IFN-Is 
after IFNAR blocking that overcomes the benefit of  reversed T cell response in viral inhibition. It is also 
important to point out that the human immunity developed in hu-mice is not fully functional, as found in 
immunocompetent hosts (24, 25). The restored anti–HIV-1 T cell immune response by IFNAR blockade in 
hu-mice may not be sufficiently robust to control HIV-1 replication.
A recent report showed that blockade of  IFNAR2 during the chronic phase of  HIV-1 infection in 
hu-mice led to decreased viral replication, diminished HIV-1–driven immune activation, and restored HIV-
1–specific CD8+ T cell function (43). The difference between the 2 studies is that Zhen et al. used a mAb to 
block IFNAR2, while we used a mAb to block IFNAR1. As reported previously, IFN-β can specifically and 
uniquely bind to IFNAR1 to initiate downstream signaling in an IFNAR2-independent manner (44). It is 
thus likely that blocking IFNAR1, but not IFNAR2, can completely block all types of  IFN-I signaling. The 
remaining IFN-I signaling that cannot be blocked by anti-IFNAR2 mAb in the report by Zhen et al. may 
still contribute to the suppression of  HIV-1 replication. Interestingly, HIV-specific CD8+ T cell function 
was restored either by IFNAR1 blockade or by IFNAR2 blockade. The reversed anti–HIV-1 T cell function 
may synergize with the remaining IFN-I signaling to further control HIV-1 replication (43). Thus, it will be 
important to dissect the specific IFN-I subtypes, their signaling pathways, and ISGs that contribute to viral 
inhibition and host immunity impairment during persistent HIV-1 infection.
During the acute phase (0–4 wpi) of  SIV infection, blocking IFN-I signaling with IFN-α2/IFN-ant, 
with increased IFNAR2 binding but diminished IFNAR1 binding activity (22), leads to elevated SIV 
replication and accelerated disease progression in rhesus monkeys (7). In the same study, they report 
that, while administration of  PEG-IFN-α2a during preinfection and acute infection results in decreased 
SIV transmission, continued IFN-α2a treatment appears to induce IFN-I desensitization and to decrease 
antiviral gene expression, also resulting in increased SIV replication and accelerated CD4+ T cell loss (7). 
This study has at least one major difference from our study in that IFN-I signaling was blocked only during 
acute SIV infection. In the absence of  IFN-I blocking during the late stage of  infection, the higher levels of  
SIV infection (probably also with higher IFN-I activity) may lead to the accelerated disease progression. It 
is generally believed that chronic IFN-I signaling during persistent infection can lead to general immune 
suppression (40). Thus, IFN-I signaling is beneficial during the acute phase to inhibit HIV-1 infection and 
to prime host immune responses, but becomes harmful during the chronic phase of  infection. Blocking 
IFN-I signaling with either the anti-INFAR1 or anti-IFNAR2 mAb in rhesus monkeys during chronic SIV 
infection will be of  great interest to further clarify these findings.
Interestingly, a TLR7 and TLR9 antagonist in SIV-infected monkeys inhibits IFN-I production by 
pDCs but does not affect viral load, immune activation, and CD4+ T cell loss (45). This suggests that 
cells other than pDCs, including myeloid DCs (mDCs), may also produce IFN-Is during persistent SIV 
infection. The TLR7 and TLR 9 antagonist fails to block IFN-I production by mDCs (45). Thus, IFN-Is 
induced by SIV infection in pDCs and other cell types may contribute to the pathogenesis of  SIV infection.
In summary, we report that IFN-Is function as a double-edged sword during persistent HIV-1 infection. 
They are beneficial by inhibiting HIV-1 replication but detrimental by inducing T cell depletion and 
dysfunction. In HIV-1–infected patients, despite efficient suppression of  HIV-1 replication with combined 
antiretroviral therapy, slightly elevated levels of  IFN-Is and ISGs persist in some individuals (46, 47), 
which may impede immune recovery and foster viral persistence (4, 48). Our recent study indicates 
that blocking IFN-I signaling during antiretroviral therapy enhances T cell recovery and reduces HIV-1 
reservoirs (23). It is conceivable that blocking IFNAR may provide a novel approach to facilitate recovery 
of  functional anti–HIV-1 immune responses, thereby enabling control of  HIV-1 reservoirs to achieve an 
HIV-1 cure, as well as to treat those immune nonresponder patients with elevated IFN-I signaling despite 
effective antiretroviral therapy.
Methods
Construction of  hu-mice. NRG (NOD-Rag2–/– γc–/–) and NSG-A2 (NOD.Cg-Prkdcscid γc–/– Tg (HLA-A2.1) 
mice were obtained from the Jackson Laboratory. Humanized NRG/NSG-A2 mice with a functional 
human immune system were generated by intrahepatic injection of  newborn mice with human fetal 
liver–derived CD34+ hematopoietic progenitor cells as previously reported (38). Humanized bone 
marrow/liver/thymus (BLT) mice were generated as previously reported (26). Briefly, 6- to 8-week-old 
NRG mice were sublethally irradiated and anesthetized, and ~1-mm3 fragments of  human fetal thymus 
were implanted under the kidney capsule. CD34+ hematopoietic progenitor cells purified from fetal 
liver of  the same donor were injected i.v. within 3 hours. Human immune cell engraftment was detected 
by flow cytometry 10–12 weeks after transplantation. All mice were housed and bred in a specific 
pathogen–free environment.
HIV-1 infection of  hu-mice. The CCR5-tropic strain of  HIV-1 (JR-CSF) was generated by transfection 
of  293T cells (ATCC) with plasmid containing full-length HIV-1 (JR-CSF) genome. Hu-mice with stable 
human leukocyte reconstitution were anesthetized and infected with HIV-1 (JR-CSF) (10 ng p24/mouse) 
through retro-orbital injection. Hu-mice infected with 293T supernatant were used as mock control groups.
Development of  anti-IFNAR1 mAb. The generation of  the anti-IFNAR1 mAb was performed as reported 
(23). Briefly, the mouse cell line L-929 transfected with the human IFNAR1 (extracellular domain and 
transmembrane domain) expression plasmid was used as the immunogen for immunization with CpG-
1826 as adjuvant. After 5 immunizations, the spleen cells were fused with the mouse myeloma cell line 
SP2/0. 293T cells transfected with the human IFNAR1 expression plasmid were used for screening the 
clones that could secret the IFNAR1-binding antibody by flow cytometry. Then, an IFN-I reporter 293T 
cell line, which had been stably transfected with a mouse Mx2 promoter–driven EGFP, was used to screen 
mAb clones that could block the human IFNAR1 signaling.
In vivo IFNAR1-blocking mAb treatments. To confirm the in vivo neutralizing activity of  the mAb, hu-mice 
were treated i.p. with mAb 6 hours prior to R848 treatment. To block IFN-I signaling during chronic HIV-1 
infection, hu-mice were treated i.p. with IFNAR1-blocking mAbs twice per week with 400 μg/mouse at 
the first injection and 200 μg/mouse for the following treatments from 6 to 10 wpi. Cohorts of  mice were 
randomized into different treatment groups by the level of  HIV-1 RNA in plasma.
Quantification of  mRNA expression by real-time reverse transcription PCR. RNA from PBMCs or whole splenocytes 
from hu-mice was isolated with the RNeasy Plus extraction kit (Qiagen) and converted to cDNA by reverse 
transcription with random hexamers and SuperScript III First-Strand Synthesis (Invitrogen). cDNA was then 
analyzed by real-time PCR using gene-specific primers for ISG15 (5′-CGCAGATCACCCAGAAGATCG-3′ 
and 5′-TTCGTCGCATTTGTCCACCA-3′), MxA (5′-GGTGGTCCCCAGTAATGTGG-3′ and 
5′-CGTCAAGATTCCGATGGTCCT-3′), OAS1 (5′-TGTCCAAGGTGGTAAAGGGTG-3′ and 
5′-CCGGCGATTTAACTGATCCTG-3′), IFITM3 (5′-ATGTCGTCTGGTCCCTGTTC-3′ and 
5′-GTCATGAGGATGCCCAGAAT-3′), Mx2 (5′-CAGAGGCAGCGGAATCGTAA-3′ and 
5′-TGAAGCTCTAGCTCGGTGTTC-3′), Trim22 (5′-CTGTCCTGTGTGTCAGACCAG-3′ and 
5′-TGTGGGCTCATCTTGACCTCT-3′), and IRF7 (5′-GCTGGACGTGACCATCATGTA-3′ and 
5′-GGGCCGTATAGGAACGTGC-3′). The ISG expression levels were normalized to human CD45 
controls. Results were calculated as a fold change in gene expression, relative to mock mice using the delta-
delta Ct method of  analysis (49).
Flow cytometry. FITC-conjugated anti–human HLA-DR (L243), IFN-γ (4S.B3), PE-conjugated 
anti–human CD38 (HIT2), PerCP/Cy5.5-conjugated anti–human CD4 (RPA-T4), PE/Cy7-conjugated 
anti–human CD8 (HIT8a), IL-2 (MQ1-17H12), BV421-conjugated anti–human PD-1 (EH12.2H7), 
APC-conjugated anti–human Ki-67 (Ki-67), and APC/Cy7-conjugated anti–human CD45 (HI30) were 
purchased from Biolegend. FITC-conjugated anti-HIV-1 p24 was purchased from Beckman Coulter. 
PE-conjugated anti–human active caspase-3 (C92-605) was purchased from BD Pharmingen. Pacific 
orange–conjugated anti–mouse CD45 (30-F11), PE/Texas red-conjugated anti–human CD3 (7D6), and 
a LIVE/DEAD Fixable Yellow Dead Cell Stain Kit were purchased from Invitrogen. PE-conjugated 
A*02:01/SLYNTVATL pentamer was purchased from PROIMMUNE.
For surface staining, single-cell suspensions prepared from peripheral blood, spleen, or mLNs of  
hu-mice were stained with surface markers and analyzed on a CyAn ADP flow cytometer (Dako). For 
intracellular staining, cells were first stained with surface markers, and then fixed and permeabilized with 
Cytofix/Cytoperm buffer (BD Bioscience), followed by intracellular staining. PE-conjugated anti–human 
active caspase-3 (C92-605) was used to detect intracellular activation of  caspase-3. Fluorescently labeled 
inhibitors of  caspase-1 (FLICA 660 Caspase-1 Assay Kit, ImmunoChemistry Technologies) were used to 
determine intracellular activation of  caspase-1. Data were analyzed using Summit4.3 software (Dako).
T cell stimulation and intracellular cytokine staining. For nonspecific stimulation, splenocytes from hu-mice 
were stimulated ex vivo with PMA (50 ng/ml) and ionomycin (1 μM) (Sigma-Aldrich) for 4 hours in 
the presence of  brefeldin A (Biolegend). For antigen-specific stimulation, splenocytes from hu-mice were 
stimulated ex vivo with peptide pools (2 μg/ml for each peptide) for HIV-1 GAG protein [PepMix HIV 
(GAG) Ultra, JPT Innovation Peptide Solutions] for 3 hours without brefeldin A and then 5 hours in 
the presence of  brefeldin A. Cells were then fixed and permeabilized with Cytofix/Cytoperm buffer, and 
intracellular staining was then performed.
HIV-1 genomic RNA detection in plasma. HIV-1 RNA was purified from plasma with the QIAamp Viral RNA 
Mini Kit (Qiagen). The RNA was then reverse transcribed and quantitatively detected by real-time PCR using 
the TaqMan Fast Virus 1-Step PCR kit (ThermoFisher Scientific). The primers used for detecting the HIV 
Gag gene were 5′-GGTGCGAGAGCGTCAGTATTAAG-3′ and 5′-AGCTCCCTGCTTGCCCATA-3′. 
The probe FAM-AAAATTCGGTTAAGGCCAGGGGGAAAGAA-QSY7 used for detection was 
ordered from Applied Biosystems and the reactions were set up according to the manufacturer’s guidelines 
and were run on the QuantStudio 6 Flex PCR system (Applied Biosystems).
Detection of  cytokines in plasma. Human pan IFN-α (subtypes 1/13, 2, 4, 5, 6, 7, 8, 10, 14, 16, and 17) 
were detected by ELISA using human IFN-α pan ELISA kits purchased from Mabtech. Human IFN-β was 
detected by ELISA using the Verikine-HS Human Interferon Beta Serum ELISA kit. Human IFN-γ, TNF-α, 
IP-10, and MCP-1 in plasma of  hu-mice were detected by Luminex immunology multiplex assay (Millipore).
Ex vivo assays. Splenocytes from mock or persistently HIV-1 infected (15–20 wpi) hu-mice were cultured 
with 20 U/ml of  IL-2 (NIH AIDS Reagent Program) ex vivo in the presence of  murine IgG2a control 
(10 μg/ml, Bio X Cell), anti-IFNAR1 (10 μg/ml), or IFN-α (200 U/ml, PBL Assay Science), caspase-3 
inhibitor Z-DEVD-FMK (10 μM), caspase-1 inhibitor Ac-YVAD-CMK (50 μM) (both Enzo Life Sciences), 
or DMSO (Sigma-Aldrich) as control for 10 days. Media were half-changed every 2 to 3 days. At day 10, 
the cells were counted and used for staining.
Statistics. In all experiments, significance levels of  data were determined by using Prism5 (GraphPad 
Software). Experiments were analyzed by 2-tailed Student’s t test, or by 1-way ANOVA and Bonferroni’s 
post hoc test according to the assumptions of  the test, as indicated for each experiment. Correlations 
between variables were evaluated using the Spearman rank correlation test. A P value less than 0.05 was 
considered significant. The number of  animals and replicates is specified in each figure legend.
Study approval. Human fetal liver and thymus (gestational age of 16 to 20 weeks) were obtained from medically 
or elective indicated termination of pregnancy through a nonprofit intermediary working with outpatient clinics 
(Advanced Bioscience Resources). Written informed consent of the maternal donors was obtained in all cases, 
under regulations governing the clinic. The project was reviewed by the University’s Office of Human Research 
Ethics, which has determined that this submission does not constitute human subjects research as defined under 
federal regulations [45 CFR 46.102(d or f) and 21 CFR 56.102(c), (e), and (l)]. All animal studies were approved 
by the University of North Carolina Institutional Animal Care and Use Committee (IACUC ID: 14-100) and 
were conducted following NIH guidelines for housing and care of laboratory animals.
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